More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

Contributed by: PR Newswire

Tags

BioArtic-AAIC

More Like This

Long-term lecanemab data show increased patient benefit with maintained safety profile

Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile

New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment

BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile

First patient treated with Leqembi® (lecanemab) in the Nordics

Long-term treatment data for lecanemab to be presented at AAIC 2024

New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress

Lecanemab four-year efficacy and safety data to be presented at AAIC 2025